Dr. Andrew is an SBIR expert with a broad range of knowledge and skills that can strategically align SBIR projects with investor and market needs. Dr. Andrew is perfect for your SBIR grant writing project because he combines scientific expertise, practical knowledge of the SBIR program, and real world commercialization experience along with a proven track record.
Dr. Andrew has been a serial entrepreneur in biotechnology companies, specializing in creating and/or identifying early value and effectiveness with therapies in disease areas that have a high unmet clinical need. As an experienced CEO, he is recognized by his peers as a leader in this field. The combination of Dr. Andrew’s business acumen and scientific expertise is a critical strategic combination for early stage companies. Dr. Andrew sits on the Boards and acts as an advisor for several companies. During his career, Dr. Andrew has successfully entered into early stage partnerships with Pharma companies to progress projects and understand how to position projects effectively.
Dr. Andrew is a registered Pharmacist, having been awarded a degree in Pharmacy by Strathclyde University in 1998. Dr. Andrew was awarded his PhD in Medicine from Glasgow University in 2005. In addition, Dr. Andrew was an Assistant Professor and Researcher at Brown University, where he invented novel treatments for stroke, autism and glaucoma. Dr. Andrew also created and taught courses on Learning and Memory, and on Pharmacology. Dr. Andrew has diverse experience, including ophthalmology, CNS, Pulmonology, drug delivery, GMO technology and oncology. Dr. Andrew has published papers and patents describing his work.
SBIR track record: Dr. Andrew has served as an NSF and NIH SBIR grant scientific reviewer over the last 5 years. He has a successful track record in SBIR grant writing and funding dating to 2010 as an awardee. His first SBIR grant was focused upon a peptide drug for ischemic stroke. This was recently reviewed for a Phase 2 award of ~$3m by NINDS with Dr. Andrew as PI and was scored a near-perfect ‘15’. In addition, Dr. Mallon has had 2 recent Cystic Fibrosis Phase 1 SBIRs that covered the development of two parallel CF programs (NIDDK and NHLBI). Both SBIRs were completed successfully. Dr. Andrew has a track record of planning and successfully leading preclinical programs that lead to viable commercial opportunities for investors and Phase 2 projects. Dr. Andrew is expert at writing both research plans and commercialization plans, and building and describing teams and environments for successful projects.
To work with SBIR Grant Writer Dr. Andrew, please visit our quote page and request him there.